Fabentech

Developing polyclonal antibodies to treat infectious diseases such as avian influenza, ebola etc.

placeLyon, Auvergne Rhone Alpes, France calendar_todayFounded 2009 groups54 employees language fabentech.com

Social engagement

Social engagement: 7.2K social following, 9 posts in the last 12 months — below the industry typical range.

Investor mix

7 investors on record.

Investor typeCountShare
Venture capital343%
Private equity229%
Other / undisclosed229%

Recent activity

18 May 2026
Event
7th International CBRNe Research & Innovation Conference
Coming soon